Spectrum Pharmaceuticals Appoints Nora Brennan to Board of Directors
December 14 2020 - 7:00AM
Business Wire
Spectrum Pharmaceuticals (NasdaqGS: SPPI) a biopharmaceutical
company focused on novel and targeted oncology therapies, today
announced the appointment of Nora Brennan to its Board of
Directors. Ms. Brennan fills a vacancy left by Ms. Elizabeth
Czerepak, who retired from the Board effective December 10,
2020.
“We are delighted to have Ms. Brennan join Spectrum’s Board of
Directors as the company continues to focus its development efforts
on novel treatments for patients with cancer,” said William Ashton,
Chairman of the Board, Spectrum Pharmaceuticals. “Her leadership
and experience in the pharmaceutical and medical technology sectors
make her an ideal contributor to our future growth. We would also
like to thank Ms. Czerepak for her dedicated service and numerous
contributions to the Board, and we wish her well in all of her
future endeavors.”
Nora Brennan is an experienced life sciences executive and
currently serves as Chief Financial Officer of TELA Bio, Inc., a
commercial stage medical device company. Ms. Brennan has extensive
financial experience of more than 20 years, and she has held
leadership roles across the healthcare and banking industries for
both private and public global companies. Prior to joining TELA,
Ms. Brennan served as Chief Financial Officer at Xeris
Pharmaceuticals, Inc., a specialty pharmaceutical company, where
she led the finance function and execution of corporate strategy,
including its initial public offering. Previously, she was employed
at Integra Lifesciences Corporation, a global medical device
company, where she held various senior leadership roles, including
Senior Vice President, Investor Relations and Corporate Treasurer.
Prior to joining Integra, Ms. Brennan worked at Citigroup and JP
Morgan in various finance and investment banking roles. Ms. Brennan
holds a Master of Business Administration degree from the
University of Chicago Booth School of Business and a Bachelor of
Arts from the University of Illinois.
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a biopharmaceutical company focused
on acquiring, developing, and commercializing novel and targeted
oncology therapies. Spectrum has a strong track record of
successfully executing across the biopharmaceutical business model,
from in-licensing and acquiring differentiated drugs, clinically
developing novel assets, successfully gaining regulatory approvals
and commercializing in a competitive healthcare marketplace.
Spectrum has a late-stage pipeline with novel assets that serve
areas of unmet need. This pipeline has the potential to transform
the company in the near future. For additional information on
Spectrum Pharmaceuticals, please visit www.sppirx.com.
Notice Regarding Forward-Looking Statements
This press release may contain forward-looking statements
regarding future events and the future performance of Spectrum
Pharmaceuticals that involve risks and uncertainties that could
cause actual results to differ materially. These statements are
based on management's current beliefs and expectations. These
statements include, but are not limited to, statements that relate
to Spectrum’s business and its future, including certain company
milestones, Spectrum's ability to identify, acquire, develop and
commercialize a broad and diverse pipeline of late-stage clinical
and commercial products, the timing and results of FDA decisions,
and any statements that relate to the intent, belief, plans or
expectations of Spectrum or its management, or that are not a
statement of historical fact. Risks that could cause actual results
to differ include the possibility that Spectrum’s existing and new
drug candidates may not prove safe or effective, the possibility
that our existing and new applications to the FDA and other
regulatory agencies may not receive approval in a timely manner or
at all, the possibility that our existing and new drug candidates,
if approved, may not be more effective, safer or more cost
efficient than competing drugs, the possibility that our efforts to
acquire or in-license and develop additional drug candidates may
fail, our dependence on third parties for clinical trials,
manufacturing, distribution and quality control and other risks
that are described in further detail in the company's reports filed
with the Securities and Exchange Commission. The company does not
plan to update any such forward-looking statements and expressly
disclaims any duty to update the information contained in this
press release except as required by law.
SPECTRUM PHARMACEUTICALS, INC.® is a registered trademark of
Spectrum Pharmaceuticals, Inc. and its affiliates. REDEFINING
CANCER CARE™ and the Spectrum Pharmaceuticals’ logos are trademarks
owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are
the property of their respective owners.
© 2020 Spectrum Pharmaceuticals, Inc. All Rights Reserved
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201214005117/en/
Robert Uhl Managing Director, Westwicke ICR 858.356.5932
robert.uhl@westwicke.com
Kurt Gustafson Chief Financial Officer 949.788.6700
InvestorRelations@sppirx.com
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Apr 2023 to Apr 2024